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Resolaris is an E.coli expressed recombinant protein derived from human histidyl-tRNA synthetase, and is 
currently in clinical development for the treatment of severe, rare myopathies with an immune component. The 
manufacturing process initially developed at laboratory scale resulted in a high degree of product purity. After 
process transfer to CMO#1 and scale-up to 225L, the purified material unexpectedly had significantly high levels 
of product related impurities. Two major impurity species were isolated and identified by peptide mapping via 
LC-MS/MS as norleucine for methionine misincorporation and a clipped form. The norleucine misincorporation 
was eliminated by amino acid supplementation during fermentation, but supplementation also increased levels 
of process impurities, later identified as RNA. The clipped form and increased RNA levels were minimized and 
controlled through modification in both fermentation and downstream procedures. Multiple GMP batches were 
manufactured (Process1.0) and product used in Phase 1/2a clinical studies.  In order to support late phase 
clinical development and commercialization, the expression vector and cell line were changed to remove the 
protease and increase productivity. In addition to the improvement in the manufacturing process, the 
manufacturing site was changed (CMO#2), and further, the drug substance and drug product formulation was 
also changed to enhance stability. Multiple batches of Resolaris have been manufactured at 2000L scale at 
CMO#2 (Process 2.0), with product output per batch increased approximately 30-fold vs. Process 1.0. In 
accordance with ICH Q5E, side-by-side analytical comparability and forced degradation studies on 
representative batches from both processes demonstrated that products from both processes are comparable 
and acceptable for late phase clinical development. 
 
 
 
 
 
